Drugs.com - New Drug Approvals

FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra

JERSEY CITY, N.J., Jan. 30, 2025 -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to...

Feb 9, 2025 - 22:25
 0
FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra
JERSEY CITY, N.J., Jan. 30, 2025 -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to...
Read More

Tags:

Previous Article

FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Mig...

Next Article

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With ...

Related Posts

FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

FDA Approves Tryngolza (olezarsen) to Reduce Triglyceri...

Feb 9, 2025  0

FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM

FDA Approves Attruby (acoramidis) to Reduce Cardiovascu...

Feb 9, 2025  0

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen...

Feb 13, 2025  0